{"id":108693,"date":"2026-02-02T12:49:29","date_gmt":"2026-02-02T11:49:29","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/orikine-bio-recibe-27-me-de-inversion-del-cdti-innovacion-con-otros-dos-inversores\/"},"modified":"2026-02-02T12:49:29","modified_gmt":"2026-02-02T11:49:29","slug":"orikine-bio-recibe-27-me-de-inversion-del-cdti-innovacion-con-otros-dos-inversores","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/es\/orikine-bio-recibe-27-me-de-inversion-del-cdti-innovacion-con-otros-dos-inversores\/","title":{"rendered":"Orikine Bio recibe 2,7 M\u20ac de inversi\u00f3n del CDTI Innovaci\u00f3n con otros dos inversores"},"content":{"rendered":"<p><strong>La empresa biotecnol\u00f3gica <a href=\"https:\/\/www.pcb.ub.edu\/es\/empresa\/orikine-bio\/\" target=\"_blank\" rel=\"noopener\">Orikine Bio<\/a>, instalada recientemente en el Parc Cient\u00edfic de Barcelona, ha recibido 2,7 millones de euros de inversi\u00f3n por parte de la SICC Innvierte del CDTI Innovaci\u00f3n junto con las gestoras de fondos Asabys Partners (Sabadell Asabys Health Innovation Investments II, FCR y Sabadell Asabys Health Innovation Investments 2B, SCR SA) y AdBio Partners (AFB Seed Fund II). Con esta inyecci\u00f3n de capital, la compa\u00f1\u00eda continuar\u00e1 impulsando el desarrollo de una nueva generaci\u00f3n de terapias para las enfermedades autoinmunes, inflamatorias y oncol\u00f3gicas.<\/strong><\/p>\n<p>El CDTI Innovaci\u00f3n, a trav\u00e9s de Innvierte, ha cerrado una operaci\u00f3n de inversi\u00f3n en esta empresa biotecnol\u00f3gica junto con Sabadell Asabys Health Innovation Investments\u202fII, FCR; Sabadell Asabys Health Innovation Investments\u202f2B, SCR\u202fSA y AFB Seed Fund\u202fII, por un importe total de 2,7 millones de euros. Gracias a esta participaci\u00f3n, el CDTI Innovaci\u00f3n contribuye a mejorar la salud y el bienestar de las personas, promoviendo el desarrollo de productos que aceleran la recuperaci\u00f3n de los pacientes.<\/p>\n<p>Su plataforma propietaria Foldikine\u2122 dise\u00f1a citocinas biespec\u00edficas, mol\u00e9culas que env\u00edan instrucciones precisas y dirigidas a las c\u00e9lulas inmunitarias de manera espec\u00edfica, eficaz y segura. Al reprogramar estas c\u00e9lulas, restauran la funci\u00f3n inmunitaria adecuada y ofrecen soluciones innovadoras para afecciones como las enfermedades autoinmunes y la inflamaci\u00f3n cr\u00f3nica.<\/p>\n<p>Con esta nueva inversi\u00f3n y el impulso tecnol\u00f3gico que representa la plataforma Foldikine\u2122, Orikine Bio refuerza su potencial de crecimiento y consolida su compromiso con el desarrollo de terapias innovadoras que mejoren la calidad de vida de las personas. La operaci\u00f3n supone un paso adelante en la traslaci\u00f3n del conocimiento cient\u00edfico hacia soluciones de alto impacto para el sistema de salud.<\/p>\n<p><strong>\u00bb Acceso a la noticia:<\/strong> <a href=\"https:\/\/www.cdti.es\/noticias\/sicc-innvierte-cdti-innovacion-invierte-orikine-bio-generacion-terapias-autoinmunes\" target=\"_blank\" rel=\"noopener\">web del CDTI [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La empresa biotecnol\u00f3gica Orikine Bio, instalada recientemente en el Parc Cient\u00edfic de Barcelona, ha recibido 2,7 millones de euros de inversi\u00f3n por parte de la SICC Innvierte del CDTI Innovaci\u00f3n&#8230;<\/p>\n","protected":false},"author":14,"featured_media":108691,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[113],"tags":[377],"class_list":["post-108693","post","type-post","status-publish","format-standard","has-post-thumbnail","category-entidades","tag-orikine"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Orikine Bio recibe 2,7 M\u20ac de inversi\u00f3n del CDTI Innovaci\u00f3n con otros dos inversores - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"description\" content=\"La compa\u00f1\u00eda continuar\u00e1 impulsando el desarrollo de nuevas terapias para las enfermedades autoinmunes, inflamatorias y oncol\u00f3gicas.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Orikine Bio recibe 2,7 M\u20ac de inversi\u00f3n del CDTI Innovaci\u00f3n con otros dos inversores - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"La compa\u00f1\u00eda continuar\u00e1 impulsando el desarrollo de nuevas terapias para las enfermedades autoinmunes, inflamatorias y oncol\u00f3gicas.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-02T11:49:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/02\/coinversion_orikine_bio-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"Orikine Bio recibe 2,7 M\u20ac de inversi\u00f3n del CDTI Innovaci\u00f3n con otros dos inversores\",\"datePublished\":\"2026-02-02T11:49:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/\"},\"wordCount\":322,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/coinversion_orikine_bio-1.jpg\",\"keywords\":[\"Orikine\"],\"articleSection\":[\"ENTIDADES\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/\",\"name\":\"Orikine Bio recibe 2,7 M\u20ac de inversi\u00f3n del CDTI Innovaci\u00f3n con otros dos inversores - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/coinversion_orikine_bio-1.jpg\",\"datePublished\":\"2026-02-02T11:49:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"description\":\"La compa\u00f1\u00eda continuar\u00e1 impulsando el desarrollo de nuevas terapias para las enfermedades autoinmunes, inflamatorias y oncol\u00f3gicas.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/coinversion_orikine_bio-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/coinversion_orikine_bio-1.jpg\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Orikine Bio recibe 2,7 M\u20ac de inversi\u00f3n del CDTI Innovaci\u00f3n con otros dos inversores\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Orikine Bio recibe 2,7 M\u20ac de inversi\u00f3n del CDTI Innovaci\u00f3n con otros dos inversores - Parc Cient\u00edfic de Barcelona","description":"La compa\u00f1\u00eda continuar\u00e1 impulsando el desarrollo de nuevas terapias para las enfermedades autoinmunes, inflamatorias y oncol\u00f3gicas.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/","og_locale":"es_ES","og_type":"article","og_title":"Orikine Bio recibe 2,7 M\u20ac de inversi\u00f3n del CDTI Innovaci\u00f3n con otros dos inversores - Parc Cient\u00edfic de Barcelona","og_description":"La compa\u00f1\u00eda continuar\u00e1 impulsando el desarrollo de nuevas terapias para las enfermedades autoinmunes, inflamatorias y oncol\u00f3gicas.","og_url":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2026-02-02T11:49:29+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/02\/coinversion_orikine_bio-1.jpg","type":"image\/jpeg"}],"author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Paula Ca\u00f1al","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"Orikine Bio recibe 2,7 M\u20ac de inversi\u00f3n del CDTI Innovaci\u00f3n con otros dos inversores","datePublished":"2026-02-02T11:49:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/"},"wordCount":322,"image":{"@id":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/02\/coinversion_orikine_bio-1.jpg","keywords":["Orikine"],"articleSection":["ENTIDADES"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/","url":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/","name":"Orikine Bio recibe 2,7 M\u20ac de inversi\u00f3n del CDTI Innovaci\u00f3n con otros dos inversores - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/02\/coinversion_orikine_bio-1.jpg","datePublished":"2026-02-02T11:49:29+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"description":"La compa\u00f1\u00eda continuar\u00e1 impulsando el desarrollo de nuevas terapias para las enfermedades autoinmunes, inflamatorias y oncol\u00f3gicas.","breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/02\/coinversion_orikine_bio-1.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/02\/coinversion_orikine_bio-1.jpg","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/es\/"},{"@type":"ListItem","position":2,"name":"Orikine Bio recibe 2,7 M\u20ac de inversi\u00f3n del CDTI Innovaci\u00f3n con otros dos inversores"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/es\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/108693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=108693"}],"version-history":[{"count":0,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/108693\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media\/108691"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=108693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/categories?post=108693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/tags?post=108693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}